



Clinical trial results:

A double-blind, placebo-controlled, randomized dose- ranging trial to investigate efficacy and safety of intravenous MIJ821 infusion in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder in subjects who have suicidal ideation with intent

Summary

EudraCT number	2020-003720-16
Trial protocol	DE SK NL PL
Global end of trial date	26 September 2023

Results information

Result version number	v1 (current)
This version publication date	09 October 2024
First version publication date	09 October 2024

Trial information

Trial identification

Sponsor protocol code	CMIJ821A12201
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04722666
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	Novartis Campus, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 September 2023
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	26 September 2023
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to investigate the dose response relationship for 4 doses (0.0048, 0.016, 0.048 and 0.16 mg/kg) of MIJ821 vs. placebo arm. The primary clinical question of interest was: what is the effect of MIJ821 versus placebo in conjunction with pharmacological standard of care (SoC) on change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at 24 hours post first dose administration, in participants with Major Depressive Disorder (MDD) who have suicidal ideation with intent, accounting for intercurrent events (IEs) with potential confounding effects and IEs leading to study discontinuation prior to the 24 hours assessment.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 July 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 5
Country: Number of subjects enrolled	Brazil: 7
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Germany: 9
Country: Number of subjects enrolled	Japan: 8
Country: Number of subjects enrolled	Malaysia: 15
Country: Number of subjects enrolled	Mexico: 31
Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	Poland: 48
Country: Number of subjects enrolled	Russian Federation: 2
Country: Number of subjects enrolled	Spain: 26
Country: Number of subjects enrolled	Taiwan: 2
Country: Number of subjects enrolled	Türkiye: 11
Country: Number of subjects enrolled	United States: 29
Worldwide total number of subjects	199
EEA total number of subjects	88

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	195
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants took part in 39 investigative sites in 14 countries.

Pre-assignment

Screening details:

The Screening period started when the participant signed the informed consent form. The eligibility of the participant was determined based on assessments performed at the Screening visit (up to 48 h) and also on Day 1 before randomization.

Period 1

Period 1 title	Core Period: 6 weeks
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	MIJ821 0.16 mg/kg bi-weekly
------------------	-----------------------------

Arm description:

MIJ821 0.16 mg/kg i.v. dose for 40 minutes on Day 1, Day 15 and Day 29

Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

MIJ821 0.16 mg/kg bi-weekly

Arm title	MIJ821 0.048 mg/kg bi-weekly
------------------	------------------------------

Arm description:

MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29

Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

MIJ821 0.048 mg/kg bi-weekly

Arm title	MIJ821 0.016 mg/kg bi-weekly
------------------	------------------------------

Arm description:

MIJ821 0.016 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29

Arm type	Experimental
----------	--------------

Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.016 mg/kg bi-weekly	
Arm title	MIJ821 0.0048 mg/kg bi-weekly
Arm description:	
MIJ821 0.0048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.0048 mg/kg bi-weekly	
Arm title	MIJ821 0.16 mg/kg single dose
Arm description:	
MIJ821 0.16 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.16 mg/kg single dose	
Arm title	MIJ821 0.048 mg/kg single dose
Arm description:	
MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.048 mg/kg single dose	
Arm title	Placebo
Arm description:	
40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	Placebo
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Number of subjects in period 1	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly
Started	30	32	25
Full Analysis and Safety Set	29	32	25
Completed	25	29	23
Not completed	5	3	2
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	3	2	1
Physician decision	2	-	-
progressive disease	-	-	1
Lost to follow-up	-	1	-

Number of subjects in period 1	MIJ821 0.0048 mg/kg bi-weekly	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose
Started	18	32	28
Full Analysis and Safety Set	18	32	28
Completed	15	28	26
Not completed	3	4	2
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	2	4	1
Physician decision	1	-	-
progressive disease	-	-	-
Lost to follow-up	-	-	1

Number of subjects in period 1	Placebo
Started	34
Full Analysis and Safety Set	33
Completed	30
Not completed	4
Adverse event, serious fatal	1
Consent withdrawn by subject	1
Physician decision	2
progressive disease	-
Lost to follow-up	-

Period 2	
Period 2 title	Extension Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor
Arms	
Are arms mutually exclusive?	Yes
Arm title	MIJ821 0.16 mg/kg bi-weekly
Arm description:	
MIJ821 0.16 mg/kg i.v. dose for 40 minutes on Day 1, Day 15 and Day 29	
Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.16 mg/kg bi-weekly	
Arm title	MIJ821 0.048 mg/kg bi-weekly
Arm description:	
MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.16 mg/kg bi-weekly	
Arm title	MIJ821 0.016 mg/kg bi-weekly
Arm description:	
MIJ821 0.016 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.016 mg/kg bi-weekly	
Arm title	MIJ821 0.0048 mg/kg bi-weekly
Arm description:	
MIJ821 0.0048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Arm type	Experimental

Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.0048 mg/kg bi-weekly	
Arm title	MIJ821 0.16 mg/kg single dose
Arm description:	
MIJ821 0.16 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.16 mg/kg single dose	
Arm title	MIJ821 0.048 mg/kg single dose
Arm description:	
MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Arm type	Experimental
Investigational medicinal product name	MIJ821
Investigational medicinal product code	MIJ821
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
MIJ821 0.048 mg/kg single dose	
Arm title	Placebo
Arm description:	
40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	Placebo
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Placebo	

Number of subjects in period 2^[1]	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly
Started	23	26	22
Completed	11	10	11
Not completed	12	16	11
Consent withdrawn by subject	3	5	1
Physician decision	-	-	1
progressive disease	1	1	3
Unsatisfactory therapeutic effect	-	1	-
Pregnancy	-	-	-
Study terminated by sponsor	7	8	4
Lost to follow-up	-	1	2
New therapy for study indication	-	-	-
Guardian decision	1	-	-
Protocol deviation	-	-	-

Number of subjects in period 2^[1]	MIJ821 0.0048 mg/kg bi-weekly	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose
Started	14	25	25
Completed	8	12	14
Not completed	6	13	11
Consent withdrawn by subject	1	2	2
Physician decision	-	1	-
progressive disease	-	-	1
Unsatisfactory therapeutic effect	-	-	-
Pregnancy	-	-	1
Study terminated by sponsor	5	9	7
Lost to follow-up	-	1	-
New therapy for study indication	-	-	-
Guardian decision	-	-	-
Protocol deviation	-	-	-

Number of subjects in period 2^[1]	Placebo
Started	28
Completed	11
Not completed	17
Consent withdrawn by subject	4
Physician decision	1
progressive disease	1
Unsatisfactory therapeutic effect	-
Pregnancy	-

Study terminated by sponsor	8
Lost to follow-up	1
New therapy for study indication	1
Guardian decision	-
Protocol deviation	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Not all participants who completed the cure study entered the extension phase

Baseline characteristics

Reporting groups	
Reporting group title	MIJ821 0.16 mg/kg bi-weekly
Reporting group description: MIJ821 0.16 mg/kg i.v. dose for 40 minutes on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.048 mg/kg bi-weekly
Reporting group description: MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.016 mg/kg bi-weekly
Reporting group description: MIJ821 0.016 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.0048 mg/kg bi-weekly
Reporting group description: MIJ821 0.0048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.16 mg/kg single dose
Reporting group description: MIJ821 0.16 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Reporting group title	MIJ821 0.048 mg/kg single dose
Reporting group description: MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Reporting group title	Placebo
Reporting group description: 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29	

Reporting group values	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly
Number of subjects	30	32	25
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	29	31	25
From 65-84 years	1	1	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	38.3	39.2	37.7
standard deviation	± 14.24	± 12.11	± 9.63
Sex: Female, Male Units: participants			
Female	16	16	12
Male	14	16	13

Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	1	0
Asian	5	4	3
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	1	0
White	24	26	22
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Reporting group values	MIJ821 0.0048 mg/kg bi-weekly	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose
Number of subjects	18	32	28
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	18	32	27
From 65-84 years	0	0	1
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	30.6	43.2	41.6
standard deviation	± 9.21	± 13.11	± 15.30
Sex: Female, Male			
Units: participants			
Female	13	18	19
Male	5	14	9
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	6	2	5
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	2
White	12	30	21
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Reporting group values	Placebo	Total	
Number of subjects	34	199	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	

Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	33	195	
From 65-84 years	1	4	
85 years and over	0	0	
Age Continuous Units: years arithmetic mean standard deviation	37.5 ± 15.42	-	
Sex: Female, Male Units: participants			
Female	15	109	
Male	19	90	
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	1	
Asian	2	27	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	5	9	
White	27	162	
More than one race	0	0	
Unknown or Not Reported	0	0	

End points

End points reporting groups

Reporting group title	MIJ821 0.16 mg/kg bi-weekly
Reporting group description: MIJ821 0.16 mg/kg i.v. dose for 40 minutes on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.048 mg/kg bi-weekly
Reporting group description: MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.016 mg/kg bi-weekly
Reporting group description: MIJ821 0.016 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.0048 mg/kg bi-weekly
Reporting group description: MIJ821 0.0048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.16 mg/kg single dose
Reporting group description: MIJ821 0.16 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Reporting group title	MIJ821 0.048 mg/kg single dose
Reporting group description: MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Reporting group title	Placebo
Reporting group description: 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.16 mg/kg bi-weekly
Reporting group description: MIJ821 0.16 mg/kg i.v. dose for 40 minutes on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.048 mg/kg bi-weekly
Reporting group description: MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.016 mg/kg bi-weekly
Reporting group description: MIJ821 0.016 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.0048 mg/kg bi-weekly
Reporting group description: MIJ821 0.0048 mg/kg dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29	
Reporting group title	MIJ821 0.16 mg/kg single dose
Reporting group description: MIJ821 0.16 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Reporting group title	MIJ821 0.048 mg/kg single dose
Reporting group description: MIJ821 0.048 mg/kg dose for 40 minutes IV infusion on Day 1 and 0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29	
Reporting group title	Placebo
Reporting group description: 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29	
Subject analysis set title	MIJ821 0.16 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.16 mg/kg i.v. dose for 40 minutes

Subject analysis set title	MIJ821 0.048 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.048 mg/kg dose for 40 minutes IV infusion

Subject analysis set title	MIJ821 0.016 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.016 mg/kg dose for 40 minutes IV infusion

Subject analysis set title	MIJ821 0.0048 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.0048 mg/kg dose for 40 minutes IV infusion

Subject analysis set title	MIJ821 0.16 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.16 mg/kg i.v. dose for 40 minutes

Subject analysis set title	MIJ821 0.048 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.048 mg/kg dose for 40 minutes IV infusion

Subject analysis set title	MIJ821 0.016 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.016 mg/kg dose for 40 minutes IV infusion

Subject analysis set title	MIJ821 0.0048 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.0048 mg/kg dose for 40 minutes IV infusion

Subject analysis set title	MIJ821 0.16 mg/kg
Subject analysis set type	Intention-to-treat

Subject analysis set description:

MIJ821 0.16 mg/kg i.v. dose for 40 minutes

Primary: Change from baseline in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS)

End point title	Change from baseline in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS) ^{[1][2]}
-----------------	--

End point description:

The Montgomery Åsberg Depression Rating Scale (MADRS, SIGMA version), is a clinician rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 - 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts and suicidal thoughts. The MADRS was collected electronically by qualified personnel.

Since the MADRS total score at 24 hours was evaluated post the single first infusion (prior to the second infusion), the bi-weekly and single dosing regimens of the same dose level are pooled as one arm for 0.048 mg/kg and 0.16 mg/kg.

End point type	Primary
----------------	---------

End point timeframe:

Baseline, 24 hours

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis not performed for terminated trial.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: arms were pooled

End point values	Placebo	MIJ821 0.16 mg/kg	MIJ821 0.048 mg/kg	MIJ821 0.016 mg/kg
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	33	61	60	25
Units: unit on a scale				
least squares mean (standard error)	-17.5 (± 1.60)	-16.4 (± 1.18)	-17.2 (± 1.19)	-17.7 (± 1.84)

End point values	MIJ821 0.0048 mg/kg			
Subject group type	Subject analysis set			
Number of subjects analysed	18			
Units: unit on a scale				
least squares mean (standard error)	-12.7 (± 2.19)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI) during the core period

End point title	Number of participants with treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI) during the core period
-----------------	--

End point description:

Treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESIs) in Core period

End point type	Secondary
----------------	-----------

End point timeframe:

6 weeks

End point values	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly	MIJ821 0.0048 mg/kg bi-weekly
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	32	25	18
Units: participants				
Number of participants with at least one TEAE	19	24	15	14
TEAEs leading to study treatment discontinuation	0	0	0	0

Treatment-emergent serious adverse events	1	0	2	3
any adverse event of special interest (AESIs)	15	8	9	7
Blood Pressure Increased (AESIs)	2	3	1	0
Cystitis (AESIs)	0	0	1	2
Dissociative reaction (AESIs)	11	3	4	1
Memory gaps Amnesia (AESIs)	5	0	1	0
QTc prolongation (AESIs)	0	0	0	0
Sedation (AESIs)	4	3	1	2
Suicidality (AESIs)	2	0	3	3

End point values	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	28	33	
Units: participants				
Number of participants with at least one TEAE	16	23	16	
TEAEs leading to study treatment discontinuation	0	0	0	
Treatment-emergent serious adverse events	0	1	3	
any adverse event of special interest (AESIs)	7	8	8	
Blood Pressure Increased (AESIs)	1	2	0	
Cystitis (AESIs)	0	0	0	
Dissociative reaction (AESIs)	4	4	4	
Memory gaps Amnesia (AESIs)	1	0	0	
QTc prolongation (AESIs)	0	0	2	
Sedation (AESIs)	2	3	0	
Suicidality (AESIs)	0	1	2	

Statistical analyses

No statistical analyses for this end point

Secondary: AUClast - Pharmacokinetics (PK) of MIJ821 in plasma

End point title	AUClast - Pharmacokinetics (PK) of MIJ821 in plasma
End point description:	
AUClast of MIJ821 in plasma after 1st infusion. AUClast is the Area Under the Curve (AUC) from time zero to the last measurable concentration sampling time (tlast). Since PK was evaluated post the single first infusion, the bi-weekly and single dosing regimens of the same dose level are pooled as one arm for 0.048 mg/kg and 0.16 mg/kg.	
End point type	Secondary
End point timeframe:	
Pre-dose, 20min, 40min, 4hours and 24hours post 1st infusion	

End point values	MIJ821 0.16 mg/kg	MIJ821 0.048 mg/kg	MIJ821 0.016 mg/kg	MIJ821 0.0048 mg/kg
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	47	47	18	16
Units: h*ng/mL				
arithmetic mean (standard deviation)	347 (± 354)	112 (± 123)	28.4 (± 22.2)	14.0 (± 23.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax - Pharmacokinetics (PK) of MIJ821 in plasma

End point title	Cmax - Pharmacokinetics (PK) of MIJ821 in plasma
End point description: Cmax of MIJ821 in plasma after 1st infusion. AUClast is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration. Since PK was evaluated post the single first infusion, the bi-weekly and single dosing regimens of the same dose level are pooled as one arm for 0.048 mg/kg and 0.16 mg/kg.	
End point type	Secondary
End point timeframe: Pre-dose, 20min, 40min, 4hours and 24hours post 1st infusion	

End point values	MIJ821 0.048 mg/kg	MIJ821 0.016 mg/kg	MIJ821 0.0048 mg/kg	MIJ821 0.16 mg/kg
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	47	18	16	49
Units: ng/mL				
arithmetic mean (standard deviation)	25.4 (± 16.9)	8.35 (± 6.67)	6.02 (± 8.15)	118 (± 177)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants meeting response criteria of ≥50% reduction in MADRS total score.

End point title	Number of participants meeting response criteria of ≥50% reduction in MADRS total score.
End point description: Response criteria of ≥50% reduction from baseline in MADRS total score over time in the Core Period. The Montgomery Åsberg Depression Rating Scale (MADRS, SIGMA version), is a clinician rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test has a total possible score of 0 - 60. Higher scores represent a more severe condition.	
End point type	Secondary

End point timeframe:

6 weeks

End point values	MIJ821 0.16 mg/kg bi- weekly	MIJ821 0.048 mg/kg bi- weekly	MIJ821 0.016 mg/kg bi- weekly	MIJ821 0.0048 mg/kg bi- weekly
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	32	25	18
Units: participants				
Day 1, 4 Hours	10	14	7	1
Day 2 (24 Hours)	8	15	12	4
Day 8	10	10	11	3
Day 15, Predose	12	10	9	3
Day 15, 4 Hours	21	23	17	7
Day 22	15	17	10	5
Day 29, Predose	17	16	8	7
Day 29, 4 Hours	21	23	19	11
Day 36	15	19	14	10
Day 43	19	19	17	9

End point values	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	28	33	
Units: participants				
Day 1, 4 Hours	8	6	16	
Day 2 (24 Hours)	13	10	14	
Day 8	9	9	13	
Day 15, Predose	10	7	10	
Day 15, 4 Hours	20	17	23	
Day 22	10	8	13	
Day 29, Predose	12	10	18	
Day 29, 4 Hours	21	19	23	
Day 36	18	15	21	
Day 43	17	16	22	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants meeting criteria for sustained response of $\geq 50\%$ reduction in MADRS total score

End point title	Number of participants meeting criteria for sustained response of $\geq 50\%$ reduction in MADRS total score
-----------------	--

End point description:

Sustained response ($\geq 50\%$ reduction from baseline) from baseline in MADRS total score for a period of at least four weeks in the Core Period.

The Montgomery Åsberg Depression Rating Scale (MADRS, SIGMA version), is a clinician rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test has a total possible score of 0 - 60. Higher scores represent a more severe condition.

End point type	Secondary
----------------	-----------

End point timeframe:

6 weeks

End point values	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly	MIJ821 0.0048 mg/kg bi-weekly
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	32	25	18
Units: participants	11	11	4	3

End point values	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	28	33	
Units: participants	5	4	6	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants meeting remission criteria of MADRS total score of ≤ 12

End point title	Number of participants meeting remission criteria of MADRS total score of ≤ 12
-----------------	---

End point description:

Remission criteria of MADRS total score of ≤ 12 over time in the Core Period.

The Montgomery Åsberg Depression Rating Scale (MADRS, SIGMA version), is a clinician rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test has a total possible score of 0 - 60. Higher scores represent a more severe condition.

End point type	Secondary
----------------	-----------

End point timeframe:

6 weeks

End point values	MIJ821 0.16 mg/kg bi- weekly	MIJ821 0.048 mg/kg bi- weekly	MIJ821 0.016 mg/kg bi- weekly	MIJ821 0.0048 mg/kg bi- weekly
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	32	25	18
Units: participants				
Day 1, 4 Hours	4	5	2	0
Day 2 (24 Hours)	4	8	6	1
Day 8	5	5	4	1
Day 15, Predose	6	4	4	1
Day 15, 4 Hours	13	15	10	4
Day 22	9	7	3	2
Day 29, Predose	8	5	4	3
Day 29, 4 Hours	13	18	11	6
Day 36	8	12	6	3
Day 43	11	10	7	6

End point values	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	28	33	
Units: participants				
Day 1, 4 Hours	2	4	6	
Day 2 (24 Hours)	5	7	7	
Day 8	5	2	8	
Day 15, Predose	5	2	5	
Day 15, 4 Hours	10	10	16	
Day 22	8	3	10	
Day 29, Predose	6	2	12	
Day 29, 4 Hours	9	11	18	
Day 36	8	4	15	
Day 43	7	5	13	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants meeting sustained remission criteria of MADRS total score of ≤ 12

End point title	Number of participants meeting sustained remission criteria of MADRS total score of ≤ 12
-----------------	---

End point description:

Remission criteria of MADRS total score of ≤ 12 sustained for a period of at least four weeks in the Core Period.

The Montgomery Åsberg Depression Rating Scale (MADRS, SIGMA version), is a clinician rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test has a total possible score of 0 - 60. Higher scores represent a more severe condition.

End point type	Secondary
----------------	-----------

End point timeframe:

6 weeks

End point values	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly	MIJ821 0.0048 mg/kg bi-weekly
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	32	25	18
Units: participants	5	3	2	2

End point values	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	28	33	
Units: participants	4	1	5	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants meeting criteria for relapse in the Extension Period

End point title	Number of participants meeting criteria for relapse in the Extension Period
-----------------	---

End point description:

For participants classified as responders in the core period who entered the extension period. Response is defined as a $\geq 50\%$ reduction from the baseline MADRS score at any visit during the study. All participants meeting criteria for relapse over fixed period in the Extension Period. A relapse manifests as the appearance of new depressive symptoms or worsening of previously stable or improving MDD symptoms. During the Extension Period, participants experiencing deterioration must be assessed by the treating physician and the relapse must be confirmed by assessment with MADRS during scheduled or unscheduled visit.

End point type	Secondary
----------------	-----------

End point timeframe:

From 6 weeks up to 58 weeks

End point values	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly	MIJ821 0.0048 mg/kg bi-weekly
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	18	17	9
Units: participants	7	7	10	3

End point values	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16	16	22	
Units: participants	5	8	10	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of relapsing participants meeting response criteria after the first retreatment infusion in the extension period

End point title	Number of relapsing participants meeting response criteria after the first retreatment infusion in the extension period ^[3]
-----------------	--

End point description:

Relapsing participants meeting response criteria or remission criteria after the first infusion of MIJ821 retreatment in the Extension Period.

Response criteria ($\geq 50\%$ reduction from baseline in MADRS total score). Reinfusions are given at Day 1, 15 and 29 after relapse.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 weeks after first retreatment infusion. Timepoints are relative to first retreatment (R) infusion for each patient, including Follow Up (F/U).

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: arms were pooled

End point values	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly	MIJ821 0.0048 mg/kg bi-weekly
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	9	2
Units: participants				
Day 1 R, 4 Hours	3	5	4	0
Day 2 R (24 Hours)	5	6	6	0
Day 8 R	5	2	2	1
Day 15 R, Predose	3	4	3	0
Day 15 R, 4 Hours	4	5	7	1
Day 22 R	8	6	5	1
Day 29 R, Predose	6	5	4	0
Day 29 R, 4 Hours	8	6	5	2
Day 36 R	8	6	5	0
Day 43 R	7	5	6	1
Week 8 F/U R	1	0	0	0
Week 12 F/U R	1	0	0	0
Week 16 F/U R	1	3	0	0
Week 20 F/U R	2	4	2	0

Week 24 F/U R	4	4	2	0
Week 28 F/U R	6	2	2	1
Week 32 F/U R	5	1	4	1
Week 36 F/U R	4	2	5	1
Week 40 F/U R	4	2	1	1
Week 44 F/U R	5	2	2	0
Week 48 F/U R	4	1	2	0
Week 52 F/U R	3	1	1	1

End point values	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	10		
Units: participants				
Day 1 R, 4 Hours	1	3		
Day 2 R (24 Hours)	2	5		
Day 8 R	2	1		
Day 15 R, Predose	2	2		
Day 15 R, 4 Hours	2	7		
Day 22 R	2	2		
Day 29 R, Predose	2	2		
Day 29 R, 4 Hours	4	6		
Day 36 R	2	5		
Day 43 R	4	5		
Week 8 F/U R	0	0		
Week 12 F/U R	0	1		
Week 16 F/U R	0	1		
Week 20 F/U R	1	4		
Week 24 F/U R	2	0		
Week 28 F/U R	5	2		
Week 32 F/U R	3	0		
Week 36 F/U R	3	0		
Week 40 F/U R	3	0		
Week 44 F/U R	1	2		
Week 48 F/U R	2	3		
Week 52 F/U R	3	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of relapsing participants meeting remission criteria after the first retreatment infusion in the extension period

End point title	Number of relapsing participants meeting remission criteria after the first retreatment infusion in the extension period ^[4]
-----------------	---

End point description:

Relapsing participants meeting response criteria or remission criteria after the first infusion of MIJ821

retreatment in the Extension Period.

Remission criteria (MADRS total score ≤ 12). Reinfusions are given at Day 1, 15 and 29 after relapse.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 weeks after first retreatment infusion. Timepoints are relative to first retreatment (R) infusion for each patient, including Follow Up (F/U).

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: arms were pooled

End point values	MIJ821 0.16 mg/kg bi- weekly	MIJ821 0.048 mg/kg bi- weekly	MIJ821 0.016 mg/kg bi- weekly	MIJ821 0.0048 mg/kg bi- weekly
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	9	2
Units: participants				
Day 1 R, 4 Hours	2	3	2	0
Day 2 R (24 Hours)	5	6	4	0
Day 8 R	3	2	1	0
Day 15 R, Predose	2	3	2	0
Day 15 R, 4 Hours	3	4	6	1
Day 22 R	5	4	3	1
Day 29 R, Predose	4	4	2	0
Day 29 R, 4 Hours	7	5	5	1
Day 36 R	3	3	4	1
Day 43 R	6	4	5	1
Week 8 F/U R	1	0	0	0
Week 12 F/U R	1	0	0	0
Week 16 F/U R	1	3	0	0
Week 20 F/U R	2	3	0	0
Week 24 F/U R	4	4	1	0
Week 28 F/U R	3	2	1	1
Week 32 F/U R	4	1	2	1
Week 36 F/U R	4	2	3	1
Week 40 F/U R	4	2	1	1
Week 44 F/U R	4	2	2	0
Week 48 F/U R	4	1	2	0
Week 52 F/U R	3	1	1	1

End point values	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	10		
Units: participants				
Day 1 R, 4 Hours	1	1		
Day 2 R (24 Hours)	2	3		
Day 8 R	2	0		
Day 15 R, Predose	0	0		
Day 15 R, 4 Hours	3	6		

Day 22 R	1	0		
Day 29 R, Predose	2	0		
Day 29 R, 4 Hours	4	7		
Day 36 R	2	2		
Day 43 R	3	4		
Week 8 F/U R	0	0		
Week 12 F/U R	0	1		
Week 16 F/U R	0	0		
Week 20 F/U R	1	2		
Week 24 F/U R	2	1		
Week 28 F/U R	5	1		
Week 32 F/U R	3	0		
Week 36 F/U R	3	0		
Week 40 F/U R	3	0		
Week 44 F/U R	1	1		
Week 48 F/U R	2	1		
Week 52 F/U R	2	2		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period, up to a maximum duration of 58 weeks.

Adverse event reporting additional description:

Placebo responders in the Core period who were followed up in the 52-week Extension period but required to be retreated due to a relapse were randomly switched to a MIJ821 regimen. For these participants AEs that occurred after start of treatment with MIJ821 are counted under the respective MIJ821 regimen.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	26.0

Reporting groups

Reporting group title	MIJ821 0.16 mg/kg bi-weekly
-----------------------	-----------------------------

Reporting group description:

MIJ821 0.16 mg/kg bi-weekly

Reporting group title	MIJ821 0.048 mg/kg bi-weekly
-----------------------	------------------------------

Reporting group description:

MIJ821 0.048 mg/kg bi-weekly

Reporting group title	MIJ821 0.016 mg/kg bi-weekly
-----------------------	------------------------------

Reporting group description:

MIJ821 0.016 mg/kg bi-weekly

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo

Reporting group title	MIJ821 0.16 mg/kg single dose
-----------------------	-------------------------------

Reporting group description:

MIJ821 0.16 mg/kg single dose

Reporting group title	MIJ821 0.048 mg/kg single dose
-----------------------	--------------------------------

Reporting group description:

MIJ821 0.048 mg/kg single dose

Reporting group title	MIJ821 0.0048 mg/kg bi-weekly
-----------------------	-------------------------------

Reporting group description:

MIJ821 0.0048 mg/kg bi-weekly

Serious adverse events	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 31 (16.13%)	7 / 34 (20.59%)	6 / 25 (24.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Cardiac disorders			
Cardiac arrest			

subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 31 (3.23%)	1 / 34 (2.94%)	2 / 25 (8.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression suicidal			
subjects affected / exposed	2 / 31 (6.45%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	1 / 31 (3.23%)	3 / 34 (8.82%)	2 / 25 (8.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	1 / 31 (3.23%)	3 / 34 (8.82%)	3 / 25 (12.00%)
occurrences causally related to treatment / all	0 / 1	0 / 5	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 33 (24.24%)	4 / 34 (11.76%)	5 / 30 (16.67%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 33 (3.03%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression suicidal			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	1 / 30 (3.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	2 / 33 (6.06%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	5 / 33 (15.15%)	1 / 34 (2.94%)	4 / 30 (13.33%)
occurrences causally related to treatment / all	0 / 5	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	MIJ821 0.0048 mg/kg bi-weekly		
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 18 (22.22%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Depression			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Depression suicidal			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Major depression			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicidal ideation			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	MIJ821 0.16 mg/kg bi-weekly	MIJ821 0.048 mg/kg bi-weekly	MIJ821 0.016 mg/kg bi-weekly
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 31 (80.65%)	27 / 34 (79.41%)	18 / 25 (72.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal hamartoma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Phlebitis			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Hypotension			

subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	0 / 31 (0.00%)	2 / 34 (5.88%)	0 / 25 (0.00%)
occurrences (all)	0	3	0
General disorders and administration site conditions			
Illness			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	1 / 31 (3.23%)	1 / 34 (2.94%)	1 / 25 (4.00%)
occurrences (all)	1	1	1
Asthenia			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Infusion site extravasation			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Medical device site rash			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			

subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Reproductive system and breast disorders			
Intermenstrual bleeding subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Breast cyst subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Endometrial disorder subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Galactorrhoea subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Polymenorrhoea subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Vulvovaginal pruritus subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Bronchospasm subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 2	0 / 25 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Hyperventilation subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Respiratory symptom subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	1 / 25 (4.00%) 1
Rhinorrhoea			

subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Nasal obstruction subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Psychiatric disorders			
Agitation subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	5 / 31 (16.13%) 8	1 / 34 (2.94%) 1	5 / 25 (20.00%) 5
Bradyphrenia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 2	0 / 25 (0.00%) 0
Daydreaming subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	1 / 25 (4.00%) 1
Depersonalisation/derealisation disorder subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Hypnagogic hallucination subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 34 (0.00%) 0	1 / 25 (4.00%) 1
Derealisation subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Dissociation subjects affected / exposed occurrences (all)	9 / 31 (29.03%) 15	3 / 34 (8.82%) 5	4 / 25 (16.00%) 6
Dissociative amnesia subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Generalised anxiety disorder			

subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	3 / 31 (9.68%)	3 / 34 (8.82%)	2 / 25 (8.00%)
occurrences (all)	3	3	3
Illusion			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Impulsive behaviour			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Initial insomnia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	6 / 31 (19.35%)	5 / 34 (14.71%)	3 / 25 (12.00%)
occurrences (all)	6	7	3
Intentional self-injury			
subjects affected / exposed	1 / 31 (3.23%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	2	2	0
Suicidal ideation			
subjects affected / exposed	3 / 31 (9.68%)	1 / 34 (2.94%)	3 / 25 (12.00%)
occurrences (all)	3	1	4
Logorrhoea			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Major depression			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2
Nightmare			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	1 / 25 (4.00%)
occurrences (all)	0	1	1
Panic attack			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	2	0	0
Irritability			

subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Terminal insomnia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Investigations			
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	2	0
Heart rate increased			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Heart rate decreased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
C-reactive protein increased			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Hepatic enzyme increased			

subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	1	0	1
Blood pressure systolic increased			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	2	0	0
Blood pressure increased			
subjects affected / exposed	1 / 31 (3.23%)	1 / 34 (2.94%)	1 / 25 (4.00%)
occurrences (all)	2	1	1
Blood pressure diastolic increased			
subjects affected / exposed	1 / 31 (3.23%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	1	2	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Lipase increased			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Liver function test increased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	1 / 31 (3.23%)	2 / 34 (5.88%)	0 / 25 (0.00%)
occurrences (all)	1	2	0
Weight increased			
subjects affected / exposed	3 / 31 (9.68%)	4 / 34 (11.76%)	5 / 25 (20.00%)
occurrences (all)	3	4	5
White blood cell count decreased			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Post procedural erythema			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Overdose			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Ligament sprain			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	2
Sinus tachycardia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 31 (0.00%)	2 / 34 (5.88%)	0 / 25 (0.00%)
occurrences (all)	0	2	0
Nervous system disorders			
Akathisia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Amnesia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Coordination abnormal			

subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Disturbance in attention			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	3 / 31 (9.68%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	5	1	0
Dysgeusia			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Dystonia			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	4 / 31 (12.90%)	10 / 34 (29.41%)	5 / 25 (20.00%)
occurrences (all)	8	16	7
Hypoaesthesia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	4 / 31 (12.90%)	4 / 34 (11.76%)	1 / 25 (4.00%)
occurrences (all)	8	6	1
Memory impairment			
subjects affected / exposed	5 / 31 (16.13%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	7	0	1
Nerve compression			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Psychomotor hyperactivity			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Sedation			

subjects affected / exposed	1 / 31 (3.23%)	1 / 34 (2.94%)	1 / 25 (4.00%)
occurrences (all)	1	1	1
Somnolence			
subjects affected / exposed	3 / 31 (9.68%)	2 / 34 (5.88%)	0 / 25 (0.00%)
occurrences (all)	3	2	0
Syncope			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Tunnel vision			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	2	0	0
Sensory disturbance			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	2	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Leukopenia			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Hypoacusis			

subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 2	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Gastrointestinal disorders Acid peptic disease subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Colitis subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	1 / 34 (2.94%) 2	1 / 25 (4.00%) 1
Dental caries subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	5 / 34 (14.71%) 6	2 / 25 (8.00%) 2
Lip swelling subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Hypoaesthesia oral subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 2	0 / 25 (0.00%) 0
Haemorrhoids			

subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	1 / 31 (3.23%)	1 / 34 (2.94%)	2 / 25 (8.00%)
occurrences (all)	1	1	2
Dry mouth			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Pancreatic steatosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	3 / 31 (9.68%)	2 / 34 (5.88%)	1 / 25 (4.00%)
occurrences (all)	3	2	1
Paraesthesia oral			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	1	0	1
Toothache			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	1 / 25 (4.00%)
occurrences (all)	1	0	1
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			

subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Skin exfoliation subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	1 / 25 (4.00%) 1
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	1 / 25 (4.00%) 1
Haematuria subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Micturition urgency subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Urinary hesitation subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Proteinuria subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Endocrine disorders			
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Pain in jaw subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Myalgia			

subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	1 / 25 (4.00%)
occurrences (all)	0	1	1
Neck pain			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Osteoporosis			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Joint stiffness			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Influenza			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
COVID-19			
subjects affected / exposed	2 / 31 (6.45%)	1 / 34 (2.94%)	1 / 25 (4.00%)
occurrences (all)	2	1	1
Bronchitis			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	1 / 25 (4.00%)
occurrences (all)	0	1	1
Pharyngitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	0 / 25 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	2 / 25 (8.00%)
occurrences (all)	0	0	2

Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	1 / 34 (2.94%) 1	1 / 25 (4.00%) 1
Otitis media subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Paronychia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	1 / 25 (4.00%) 1
Rhinitis subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 34 (2.94%) 1	0 / 25 (0.00%) 0
Metabolism and nutrition disorders			
Dyslipidaemia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	1 / 25 (4.00%) 1
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 34 (0.00%) 0	0 / 25 (0.00%) 0
Hyperphagia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	1 / 25 (4.00%) 1
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	0 / 34 (0.00%) 0	2 / 25 (8.00%) 2
Hyperuricaemia			

subjects affected / exposed	1 / 31 (3.23%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	1	0	0
Overweight			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0
Vitamin B12 deficiency			
subjects affected / exposed	0 / 31 (0.00%)	0 / 34 (0.00%)	0 / 25 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Placebo	MIJ821 0.16 mg/kg single dose	MIJ821 0.048 mg/kg single dose
Total subjects affected by non-serious adverse events			
subjects affected / exposed	19 / 33 (57.58%)	20 / 34 (58.82%)	29 / 30 (96.67%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal hamartoma			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Phlebitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	2 / 33 (6.06%)	1 / 34 (2.94%)	2 / 30 (6.67%)
occurrences (all)	2	1	3
Hypertension			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Illness			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Gait disturbance			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	3

Asthenia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Infusion site extravasation			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Medical device site rash			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Peripheral swelling			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Intermenstrual bleeding			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Breast cyst			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Endometrial disorder			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Galactorrhoea			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Polymenorrhoea			

subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hyperventilation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Respiratory symptom			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Nasal obstruction			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	2	0	0
Anxiety			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	2 / 30 (6.67%)
occurrences (all)	0	1	3
Bradyphrenia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Daydreaming			

subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Depersonalisation/derealisation disorder			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Hypnagogic hallucination			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Derealisation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Dissociation			
subjects affected / exposed	3 / 33 (9.09%)	1 / 34 (2.94%)	4 / 30 (13.33%)
occurrences (all)	4	1	5
Dissociative amnesia			
subjects affected / exposed	1 / 33 (3.03%)	2 / 34 (5.88%)	1 / 30 (3.33%)
occurrences (all)	1	2	2
Generalised anxiety disorder			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	3 / 33 (9.09%)	1 / 34 (2.94%)	3 / 30 (10.00%)
occurrences (all)	3	1	3
Illusion			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Impulsive behaviour			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Initial insomnia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	3 / 33 (9.09%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	3	1	0

Intentional self-injury			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	1
Suicidal ideation			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	4 / 30 (13.33%)
occurrences (all)	0	1	4
Logorrhoea			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Major depression			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Nightmare			
subjects affected / exposed	0 / 33 (0.00%)	2 / 34 (5.88%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Panic attack			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Irritability			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Terminal insomnia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Investigations			
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	1 / 30 (3.33%)
occurrences (all)	0	1	2
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 33 (0.00%)	2 / 34 (5.88%)	1 / 30 (3.33%)
occurrences (all)	0	2	1
Aspartate aminotransferase increased			

subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Amylase increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Heart rate increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Heart rate decreased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood pressure systolic increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood pressure increased			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	2 / 30 (6.67%)
occurrences (all)	0	1	4
Blood pressure diastolic increased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Blood thyroid stimulating hormone increased			

subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	1 / 33 (3.03%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	1	1	0
Liver function test increased			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Weight decreased			
subjects affected / exposed	0 / 33 (0.00%)	2 / 34 (5.88%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Weight increased			
subjects affected / exposed	5 / 33 (15.15%)	2 / 34 (5.88%)	3 / 30 (10.00%)
occurrences (all)	5	2	5
White blood cell count decreased			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Post procedural erythema			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Overdose			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Ligament sprain			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			

Palpitations			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Sinus bradycardia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Akathisia			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Amnesia			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Coordination abnormal			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Lethargy			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Dysgeusia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Dystonia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Headache			

subjects affected / exposed	4 / 33 (12.12%)	4 / 34 (11.76%)	7 / 30 (23.33%)
occurrences (all)	4	10	14
Hypoaesthesia			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	2 / 33 (6.06%)	4 / 34 (11.76%)	4 / 30 (13.33%)
occurrences (all)	2	4	4
Memory impairment			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Nerve compression			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Psychomotor hyperactivity			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Sedation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	2
Somnolence			
subjects affected / exposed	0 / 33 (0.00%)	2 / 34 (5.88%)	4 / 30 (13.33%)
occurrences (all)	0	3	5
Syncope			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Tremor			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Tunnel vision			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Sensory disturbance			

subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 34 (0.00%) 0	0 / 30 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Iron deficiency anaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	3 / 30 (10.00%)
occurrences (all)	0	0	3
Hypoacusis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Vision blurred			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Acid peptic disease			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 33 (3.03%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	1	1	0
Abdominal pain			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	1	0	2
Colitis			

subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	3
Dental caries			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	1 / 30 (3.33%)
occurrences (all)	0	1	1
Lip swelling			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Haemorrhoids			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Dry mouth			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Pancreatic steatosis			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	1 / 33 (3.03%)	2 / 34 (5.88%)	2 / 30 (6.67%)
occurrences (all)	1	2	3
Paraesthesia oral			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Vomiting			

subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	2	0
Toothache			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	2	0	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	1 / 30 (3.33%)
occurrences (all)	0	1	1
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 33 (0.00%)	2 / 34 (5.88%)	0 / 30 (0.00%)
occurrences (all)	0	3	0
Micturition urgency			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Proteinuria			

subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	1 / 34 (2.94%) 1	0 / 30 (0.00%) 0
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	1 / 34 (2.94%) 1	0 / 30 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	1 / 34 (2.94%) 1	2 / 30 (6.67%) 2
Back pain subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	1 / 34 (2.94%) 1	1 / 30 (3.33%) 1
Pain in jaw subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 34 (0.00%) 0	0 / 30 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	2 / 34 (5.88%) 3	0 / 30 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 34 (0.00%) 0	0 / 30 (0.00%) 0
Osteoporosis subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 34 (0.00%) 0	0 / 30 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 34 (0.00%) 0	1 / 30 (3.33%) 1
Joint stiffness subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 34 (0.00%) 0	0 / 30 (0.00%) 0
Infections and infestations Influenza subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 34 (0.00%) 0	0 / 30 (0.00%) 0
Conjunctivitis			

subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
COVID-19			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	2 / 30 (6.67%)
occurrences (all)	0	0	2
Bronchitis			
subjects affected / exposed	0 / 33 (0.00%)	1 / 34 (2.94%)	0 / 30 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	2 / 33 (6.06%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	2	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			

subjects affected / exposed occurrences (all)	0 / 33 (0.00%) 0	0 / 34 (0.00%) 0	0 / 30 (0.00%) 0
Metabolism and nutrition disorders			
Dyslipidaemia			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hyperphagia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 33 (0.00%)	0 / 34 (0.00%)	1 / 30 (3.33%)
occurrences (all)	0	0	1
Hyperuricaemia			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0
Overweight			
subjects affected / exposed	1 / 33 (3.03%)	1 / 34 (2.94%)	1 / 30 (3.33%)
occurrences (all)	1	1	1
Vitamin B12 deficiency			
subjects affected / exposed	1 / 33 (3.03%)	0 / 34 (0.00%)	0 / 30 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	MIJ821 0.0048 mg/kg bi-weekly		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 18 (72.22%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal hamartoma			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Phlebitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

Hypotension			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Illness			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gait disturbance			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Asthenia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Infusion site extravasation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Medical device site rash			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Peripheral swelling			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Non-cardiac chest pain			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Reproductive system and breast disorders			
Intermenstrual bleeding subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Breast cyst subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Endometrial disorder subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Galactorrhoea subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Polymenorrhoea subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Vulvovaginal pruritus subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders			
Bronchospasm subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Epistaxis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Hyperventilation subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Respiratory symptom subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Rhinorrhoea			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nasal obstruction			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Anxiety			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Bradyphrenia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Daydreaming			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Depersonalisation/derealisation disorder			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hypnagogic hallucination			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Derealisation			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Dissociation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dissociative amnesia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Generalised anxiety disorder			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Illusion			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Impulsive behaviour			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Initial insomnia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Intentional self-injury			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Suicidal ideation			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Logorrhoea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Major depression			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nightmare			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Panic attack			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Irritability			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Terminal insomnia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Investigations			
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Amylase increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Heart rate increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Heart rate decreased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
C-reactive protein increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hepatic enzyme increased			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood pressure systolic increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood pressure increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood pressure diastolic increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood phosphorus decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Liver function test increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	3		
Weight increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Post procedural erythema			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Overdose			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Sinus bradycardia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Sinus tachycardia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Akathisia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Amnesia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Coordination abnormal			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Disturbance in attention			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lethargy			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dystonia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Hypoaesthesia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Memory impairment			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Nerve compression			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Psychomotor hyperactivity			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Sedation			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Somnolence			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Syncope			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tunnel vision			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Sensory disturbance			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Iron deficiency anaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Leukopenia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hypoacusis			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Gastrointestinal disorders Acid peptic disease subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Abdominal pain subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Colitis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Constipation subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Dental caries subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Diarrhoea subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Lip swelling subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Hypoaesthesia oral subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Haemorrhoids			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dry mouth			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pancreatic steatosis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	5		
Paraesthesia oral			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Toothache			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dermatitis allergic			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hyperhidrosis			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Skin exfoliation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 18 (5.56%)</p> <p>1</p> <p>0 / 18 (0.00%)</p> <p>0</p>		
<p>Renal and urinary disorders</p> <p>Dysuria</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Haematuria</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Micturition urgency</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Urinary hesitation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Proteinuria</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 18 (5.56%)</p> <p>1</p> <p>0 / 18 (0.00%)</p> <p>0</p> <p>1 / 18 (5.56%)</p> <p>1</p> <p>1 / 18 (5.56%)</p> <p>1</p> <p>0 / 18 (0.00%)</p> <p>0</p>		
<p>Endocrine disorders</p> <p>Hypothyroidism</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 18 (0.00%)</p> <p>0</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Back pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pain in jaw</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Myalgia</p>	<p>1 / 18 (5.56%)</p> <p>1</p> <p>0 / 18 (0.00%)</p> <p>0</p> <p>0 / 18 (0.00%)</p> <p>0</p>		

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Osteoporosis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Joint stiffness			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Infections and infestations			
Influenza			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
COVID-19			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Bronchitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pharyngitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Respiratory tract infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Otitis media subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Paronychia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Rhinitis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Metabolism and nutrition disorders			
Dyslipidaemia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Hyperphagia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Hyperuricaemia			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Overweight			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vitamin B12 deficiency			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 June 2021	<ul style="list-style-type: none">• Inclusion and exclusion criteria were updated to align with the current product labelling medications.• The infusion device compatibility studies performed to date do not cover the patients with body weight below 50 kg and above 120 kg. Hence, the relapsing patients were not allowed to be retreated if their body weight is no longer within the allowed range of 50-120 kg.• List of prohibited medications was updated to include the medications with additive effect on cardiac safety. Rescue medications were added not only for agitation, anxiety but also for aggressive behavior and the clarification for benzodiazepines was provided.• The requirement of prohibiting changes to psychotherapy treatment was removed to align with clinical practice and facilitate recruitment of patients who received psychotherapy at the time of study initiation.• Audio-recording and independent analysis of S-STS scale assessments were included.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported